5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies

Modern Pathology

Volumn 28, Issue 2, 2015, Pages 218-229

  Lee, Jonathan J ^a   Granter, Scott R ^a   Laga, Alvaro C ^a   Saavedra, Arturo P ^a   Zhan, Qian ^a   Guo, Weimin ^a   Xu, Shuyun ^a   Murphy, George F ^a   Lian, Christine G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; MELAN A; TUMOR MARKER; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE;

ADULT; AGED; ARTICLE; CANCER STAGING; CUTANEOUS MELANOMA; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTE; METASTATIC MELANOMA; NEVUS; PRIMARY TUMOR; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TUMOR DIAGNOSIS; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; FLUORESCENT ANTIBODY TECHNIQUE; LYMPH NODE; LYMPHATIC METASTASIS; MELANOMA; MIDDLE AGED; PATHOLOGY; SKIN NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CYTOSINE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEVUS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 84922019757     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.99     Document Type: Article

References (23)

1. Piris A, Mihm MC Jr., Duncan LM. AJCC melanoma staging update: impact on dermatopathology practice and patient management. J Cutan Pathol 2011;38: 394-400.
2. Carson KF, Wen DR, Li PX, et al. Nodal nevi and cutaneous melanomas. Am J Surg Pathol 1996;20: 834-840.
3. Fontaine D, Parkhill W, Greer W, et al. Nevus cells in lymph nodes: an association with congenital cutaneous nevi. Am J Dermatopathol 2002;24:1-5.
4. Gambichler T, Scholl L, Stucker M, et al. Clinical characteristics and survival data of melanoma patients with nevus cell aggregates within sentinel lymph nodes. Am J Clin Pathol 2013;139:566-573.
5. Chen PL, Chen WS, Li J, et al. Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas. Mod Pathol 2013;26:44-53.
6. Holt JB, Sangueza OP, Levine EA, et al. Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi. Am J Clin Pathol 2004;121:58-63.
7. Mihic-Probst D, Saremaslani P, Komminoth P, et al. Immunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus. Virchows Arch 2003;443:745-751.
8. Blokhin E, Pulitzer M, Busam KJ. Immunohistochemical expression of p16 in desmoplastic melanoma. J Cutan Pathol 2013;40:796-800.
9. Dalton SR, Gerami P, Kolaitis NA, et al. Use of fluorescence in situ hybridization (FISH) to distinguish intranodal nevus from metastatic melanoma. Am J Surg Pathol 2010;34:231-237.
10. Laga AC, Zhan Q, Weishaupt C, et al. SOX2 and nestin expression in human melanoma: an immunohistochemical and experimental study. Exp Dermatol 2011;20:339-345.
11. Girouard SD, Laga AC, Mihm MC, et al. SOX2 contributes to melanoma cell invasion. Lab Invest 2012;92: 362-370.
12. Larson AR, Dresser KA, Zhan Q, et al. Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors. Mod Pathol 2014;27:936-944.
13. Lian CG, Xu Y, Ceol C, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012;150:1135-1146.
14. Wu H, Zhang Y. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell 2014;156:45-68.
15. Williams K, Christensen J, Helin K. DNA methylation: TET proteins-guardians of CpG islands? EMBO Rep 2012;13:28-35.
16. Coit DG, Andtbacka R, Anker CJ, et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11: 395-407.
17. Ulmer A, Dietz K, Hodak I, et al. Quantitative measurement of melanoma spread in sentinel lymph nodes and survival. PLoS Med 2014;11:e1001604.
18. Uchiyama R, Uhara H, Uchiyama A, et al. 5-Hydroxymethylcytosine as a useful marker to differentiate between malignant melanomas and benign melanocytic nevi. J Dermatol Sci 2014;73:161-163.
19. Haffner MC, Chaux A, Meeker AK, et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011;2:627-637.
20. Yang Q, Wu K, Ji M, et al. Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J Biomed Nanotechnol 2013;9:1607-1616.
21. Liu C, Liu L, Chen X, et al. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PloS ONE 2013;8:e62828.
22. Orr BA, Haffner MC, Nelson WG, et al. Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PloS ONE 2012;7:e41036.
23. Satzger I, Volker B, Meier A, et al. Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes. Am J Surg Pathol 2007;31:1175-1180.